{"id":"NCT00686686","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)","officialTitle":"A Multi Center, Open Label, Single-Arm Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP), Including the Pustular Form (PsPPP)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2009-02","completion":"2009-04","firstPosted":"2008-05-30","resultsPosted":"2011-02-23","lastUpdate":"2017-04-11"},"enrollment":23,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Infliximab","otherNames":["SCH 215596","Remicade"]}],"arms":[{"label":"Infliximab 5 mg/kg","type":"EXPERIMENTAL"}],"summary":"Subjects with psoriasis will receive intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 (induction therapy) to evaluate the efficacy of infliximab at Week 18. Subjects who achieved \\>=75% improvement in Psoriasis Pustulosa Palmoplantaris Area and Severity Index (PPPASI) score at Week 8 AND had deterioration of PPPASI score of 50% from Week 8 until Week 12 were to receive an additional infusion at Week 12.","primaryOutcome":{"measure":"Number of Participants Who Achieve at Least 75% Improvement in Palmoplantar Psoriasis Activity Severity Index (PPPASI) After 3 Infusions.","timeFrame":"Baseline and Week 8","effectByArm":[{"arm":"Infliximab 5 mg/kg","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":27},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":23},"commonTop":["Hepatic enzyme increased","Asthenia","Folliculitis","Liver function test abnormal"]}}